How to Assess Antidepressant Trial Generalizability for Diverse Patients
How should clinicians judge whether an antidepressant trial applies to a patient whose sex, race, or ethnicity may be underrepresented in the evidence base?
Clinicians often need to decide whether antidepressant efficacy and tolerability data are likely to translate to the patient in front of them. This is especially important in major depressive disorder when trial populations may not reflect real-world antidepressant users or local demographic populations.
-
Check whether the trial reported demographic data at all
Start by confirming whether the antidepressant trial reports sex, race, and ethnicity. In this review, sex was reported in 90.36% of trials, but race in only 39.16% and ethnicity in 33.13%, so absent reporting is itself a reason to limit confidence in subgroup generalizability.
-
Compare the enrolled population with the treated population
For sex, do not assume a trial is representative just because women slightly outnumber men. In this review, women made up 58.27% of trial participants, which was higher than the state-level population benchmark of 51.06% but lower than the national antidepressant-user benchmark of 67.30%, indicating underrepresentation relative to the population actually using antidepressants.
-
Look for underrepresented racial and ethnic groups
Be especially cautious when applying antidepressant trial findings to Asian, American Indian or Alaska Native, multiracial, and Hispanic or Latino patients. These groups were significantly underrepresented relative to state-level census benchmarks: Asian 4.13% versus 5.67%, AIAN 0.44% versus 0.89%, multiracial 1.90% versus 2.26%, and Hispanic or Latino 12.42% versus 17.20%.
-
Avoid assuming all groups were underenrolled equally
Interpret demographic gaps specifically rather than treating antidepressant trial diversity as uniformly poor across every group. In this analysis, White participants 73.10% versus 77.52%, Black participants 20.21% versus 13.51%, and Native Hawaiian and Other Pacific Islander participants 0.21% versus 0.16% did not differ significantly from the state-level benchmark overall.
-
Apply extra caution when pharmacokinetic or tolerability differences may matter
Increase caution when using trial data to guide medication selection or counseling in groups for whom the article notes possible differences in antidepressant metabolism, treatment response, tolerability, or adherence. The article specifically notes sex-related pharmacokinetic variation and possible pharmacogenomic variation involving CYP2D6 and CYP2C19 across populations, while also stating that the clinical significance of some differences remains uncertain.
Clinical Considerations
- This workflow is based on a review of ClinicalTrials.gov-registered US trials and does not capture all antidepressant research.
- Race and ethnicity analyses were limited by incomplete reporting, with many trials excluded from those comparisons because the variables were not reported.
- State-level census benchmarks were used to approximate recruitment populations, but they may not fully reflect disease burden or antidepressant use within demographic subgroups.
- The sex benchmark based on antidepressant users may have limited generalizability because one referenced prevalence cohort was mostly White, non-Hispanic, and highly educated, although the authors note similar estimates in other datasets.
Bottom Line
Before applying antidepressant trial results to an individual patient, verify who was actually enrolled and treat missing or skewed sex, race, and ethnicity data as a real limit on generalizability.
